Pharmacy · 2 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review summarizes key trials for five FDA-approved medications for dry eye disease. The central finding is that the reviewed randomized controlled trials were robust with low bias, and the medications demonstrated efficacy and minimal side effects.
This narrative review analyzed seven randomized controlled trials for five novel medications for dry eye disease: lifitegrast, cyclosporine 0.09%, loteprednol etabonate, varenicline nasal spray, and perfluorohexyloctane. The authors used the FRISBE mnemonic to appraise the trials, finding them robust with predominantly low bias. The review describes each drug's mechanism and clinical application, concluding they are safe and efficacious with minimal side effects. Limitations include the lack of head-to-head comparisons, uncertainty about combination therapy benefits, and a focus only on manufacturer-funded landmark trials. The authors conclude these medications offer effective alternatives and call for further research on long-term outcomes and comparative efficacy.
